Results 281 to 290 of about 104,328 (314)
Some of the next articles are maybe not open access.

Assessment of NLRP3 Inflammasome Activation and NLRP3-NEK7 Complex Assembly

2023
The NLRP3 inflammasome is a critical component of innate immunity that activates caspase-1 to induce inflammation in response to a wide spectrum of endogenous and exogenous stimuli. NLRP3 inflammasome activation has been shown by assays for the cleavage of caspase-1 and gasdermin D, the maturation of IL-1β and IL-18, and ASC speck formation in innate ...
Nathan, Kelley, Yuan, He
openaire   +2 more sources

Pharmacological targeting of NLRP3 deubiquitination for treatment of NLRP3-associated inflammatory diseases

Science Immunology, 2021
Thiolutin, an inhibitor of the BRISC deubiquitinating enzyme complex, specifically and potently inhibits NLRP3 inflammasome activation.
Guang-Ming Ren   +22 more
openaire   +2 more sources

Ergolide covalently binds NLRP3 and inhibits NLRP3 inflammasome-mediated pyroptosis

International Immunopharmacology, 2023
NLR family pyrin domain-containing 3 (NLRP3)-mediated pyroptosis plays a key role in various acute and chronic inflammatory diseases. Targeted inhibition of NLRP3-mediated pyroptosis may be a potential therapeutic strategy for various inflammatory diseases.
Miao Ren   +13 more
openaire   +2 more sources

Ubiquitination of NLRP3 by gp78/Insig-1 restrains NLRP3 inflammasome activation

Cell Death & Differentiation, 2022
The NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome plays a pivotal role in defending the host against infection as well as sterile inflammation. Activation of the NLRP3 inflammasome is critically regulated by a de-ubiquitination mechanism, but little is known about how ubiquitination restrains NLRP3 activity. Here, we showed that
Ting Xu   +15 more
openaire   +2 more sources

USP5 attenuates NLRP3 inflammasome activation by promoting autophagic degradation of NLRP3

Autophagy, 2021
3-MA: 3-methyladenine; AIM2: absent in melanoma 2; ATG5: autophagy related 5; BafA1: bafilomycin A1; CASP1: caspase 1; CHX: cycloheximide; Co-IP: co-immunoprecipitation; CQ: chloroquine; DUBs: deubiquitinases; IL1B/IL-1β: interleukin 1 beta; LAMP1: lysosomal associated membrane protein 1; LPS: lipopolysaccharide; MARCHF7/MARCH7: membrane associated ...
Baoshan Cai   +11 more
openaire   +2 more sources

IκBζ controls NLRP3 inflammasome activation via upregulation of the Nlrp3 gene

Cytokine, 2020
Inflammasome activation induces the maturation and secretion of interleukin (IL)-1β and -18, and is dependent on NF-κB signaling to induce the transcription of the inflammasome components, called the priming step. This study elucidated the role of IκBζ, an atypical IκBs (inhibitor of κB) and a coactivator of NF-κB target genes, on the activation of ...
Jeongeun, Kim   +9 more
openaire   +2 more sources

NLRP12 interacts with NLRP3 to block the activation of the human NLRP3 inflammasome

Science Signaling
Inflammasomes are multiprotein complexes that drive inflammation and contribute to protective immunity against pathogens and immune pathology in autoinflammatory diseases. Inflammasomes assemble when an inflammasome scaffold protein senses an activating signal and forms a signaling platform with the inflammasome adaptor protein ASC.
Coombs, Jared   +16 more
openaire   +4 more sources

The NLRP3 inflammasome: activation and regulation

Trends in Biochemical Sciences, 2023
The NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome is a cytoplasmic supramolecular complex that is activated in response to cellular perturbations triggered by infection and sterile injury. Assembly of the NLRP3 inflammasome leads to activation of caspase-1, which induces the maturation and release of interleukin-1β (IL-1β) and ...
Jie, Xu, Gabriel, Núñez
openaire   +2 more sources

Arteannuin B, a novel NLRP3 inhibitor, suppresses NLRP3 inflammasome in macrophages and alleviates NLRP3-related diseases

International Immunopharmacology
The NLRP3 inflammasome plays pivotal roles in inflammatory pathogenesis, yet developing specific inhibitors remains challenging due to toxicity risks and incomplete mechanistic targeting. FDA has authorized no NLRP3 inhibitor for therapeutic application in clinical use.
Weifeng, Li   +10 more
openaire   +2 more sources

The NLRP3 Conundrum

Arthritis & Rheumatology, 2023
James T. Rosenbaum   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy